April 30 (Reuters) - Danish drugmaker LEO Pharma said on Thursday it had agreed to buy U.S. drug developer Replay for $50 million upfront, adding an experimental treatment platform for rare genetic skin diseases to its dermatology business.

Purdue Pharma secured court approval for a $125 million settlement with McKinsey & Co. to resolve claims related to the firm’s advisory role in marketing the drugmaker’s opioids.

LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Generics battle takes center stage at SCOTUS; FDA uses AI for clinical trial review; Purdue Pharma to dissolve.

Shares of Avalyn Pharma are set to make their trading debut Thursday after the clinical-stage biopharmaceutical company's upsized initial public offering was priced at the high end of expectations, raising $300 million.

Luminous Technologies delivered a unified ServiceNow HRSD onboarding portal for a European pharma company expanding

Banking and financial services have been early adopters of technology, and they were the first ones to build data warehouses and data lakes, he said, adding that there is a lot of innovation being don